The information described in §201.66(c) of this chapter shall be printed in accordance with the following specifications.

(1) The labeling shall meet the requirements of §201.66(c) of this chapter except that the information in §201.66(c)(3) of this chapter may be omitted, and the information in §201.66(c)(5) and (c)(6) of this chapter may be presented as follows:

(i) The words “Contains salicylate.” may be omitted from the warning in §335.50(c)(2)(i)(B).

(ii) The subheading “When using this product” in §335.50(c)(2)(iv) may be omitted.

(iii) The words “continue to” may be omitted from the directions in §335.50(d)(3).

(2) The labeling shall be printed in accordance with the requirements of §201.66(d) of this chapter except that any requirements related to §201.66(c)(3) of this chapter and the bullet in the warning in §335.50(c)(1)(i) may be omitted.

[68 FR 18881, April 17, 2003, as amended at 69 FR 26302, May 12, 2004]

PART 336—ANTIEMETIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

Subpart A—General Provisions

Sec. 336.1 Scope.
336.3 Definition.

Subpart B—Active Ingredients

§336.10 Antiemetic active ingredients.

Subpart C—Labeling

§336.50 Labeling of antiemetic drug products.

(a) Statement of identity. The labeling of the product contains the established name of the drug, if any, and identifies the product as an “antiemetic.”

(b) Indications. The labeling of the product states the following under the heading “Indications.” “For the prevention and treatment of the nausea, vomiting, or dizziness associated with motion sickness.” Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in this paragraph (b), may also be used, as provided in §330.1(c)(2), subject to the provisions of section 502 of the act relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act.

(c) Warnings. The labeling of the product contains the following warnings under the heading “Warnings:”

(1) For products containing any ingredient identified in §336.10—(1) When labeled for use in adults and for those products that can be and are labeled for use in children under 12 years of age. “Do not
take this product, unless directed by a doctor, if you have a breathing problem such as emphysema or chronic bronchitis, or if you have glaucoma or difficulty in urination due to enlargement of the prostate gland."

(1) For those products that can be and are labeled only for children under 12 years of age. "Do not give this product to children who have a breathing problem such as chronic bronchitis or who have glaucoma, without first consulting the child’s doctor."

(2) For products containing cyclizine hydrochloride identified in § 336.10(a). "Do not give to children under 6 years of age unless directed by a doctor."

(3) For products containing dimenhydrinate identified in § 336.10(b). "Do not give to children under 2 years of age unless directed by a doctor."

(4) For products containing diphenhydramine hydrochloride identified in § 336.10(c). "Do not give to children under 6 years of age unless directed by a doctor."

(5) For products containing meclizine hydrochloride identified in § 336.10(d). "Do not give to children under 12 years of age unless directed by a doctor."

(6) For products containing cyclizine hydrochloride identified in § 336.10(a) or meclizine hydrochloride identified in § 330.10(d). "May cause drowsiness; alcohol, sedatives, and tranquilizers may increase the drowsiness effect. Avoid alcoholic beverages while taking this product. Do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor. Use caution when driving a motor vehicle or operating machinery."

(7) For products containing dimenhydrinate identified in § 336.10(b) or diphenhydramine hydrochloride identified in § 336.10(c). "May cause marked drowsiness; alcohol, sedatives, and tranquilizers may increase the drowsiness effect. Avoid alcoholic beverages while taking this product. Do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor. Use caution when driving a motor vehicle or operating machinery."

(8) For products containing diphenhydramine hydrochloride identified in § 336.10(c). "Do not use [bullet]1 with any other product containing diphenhydramine, including one used on skin".

(d) Directions. The labeling of the product contains the following information under the heading "Directions":

(1) For products containing cyclizine hydrochloride identified in § 336.10(a). Adults and children 12 years of age and over: Oral dosage is 50 milligrams every 4 to 6 hours, not to exceed 200 milligrams in 24 hours, or as directed by a doctor. Children 6 to under 12 years of age: Oral dosage is 25 milligrams every 6 to 8 hours, not to exceed 76 milligrams in 24 hours, or as directed by a doctor.

(2) For products containing dimenhydrinate identified in § 336.10(b). Adults and children 12 years of age and over: Oral dosage is 50 to 100 milligrams every 4 to 6 hours, not to exceed 400 milligrams in 24 hours, or as directed by a doctor. Children 6 to under 12 years of age: Oral dosage is 25 to 50 milligrams every 6 to 8 hours, not to exceed 150 milligrams in 24 hours, or as directed by a doctor. Children 2 to under 6 years of age: Oral dosage is 12.5 to 25 milligrams every 6 to 8 hours, not to exceed 75 milligrams in 24 hours, or as directed by a doctor.

(3) For products containing diphenhydramine hydrochloride identified in § 336.10(c). Adults and children 12 years of age and over: Oral dosage is 25 to 50 milligrams every 4 to 6 hours, not to exceed 150 milligrams in 24 hours, or as directed by a doctor. Children 6 to under 12 years of age: Oral dosage is 12.5 to 25 milligrams every 4 to 6 hours, not to exceed 75 milligrams in 24 hours, or as directed by a doctor.

(4) For products containing meclizine hydrochloride identified in § 336.10(d). Adults and children 12 years of age and over: Oral dosage is 25 to 50 milligrams once daily, or as directed by a doctor.

(e) The word “physician” may be substituted for the word “doctor” in any

1 See § 301.66(b)(4) of this chapter for definition of bullet symbol.
§ 336.80 Professional labeling.

The labeling provided to health professionals (but not to the general public) may contain the following additional indications.

(a) For products containing cyclizine hydrochloride, dimenhydrinate, and diphenhydramine hydrochloride identified in §336.10 (a), (b), and (c). "For the treatment of vertigo of motion sickness."

(b) For products containing meclizine hydrochloride identified in §336.10(d). "For the treatment of vertigo."

PART 338—NIGHTTIME SLEEP-AID DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

Subpart A—General Provisions

Sec. 338.1 Scope.
338.3 Definition.

Subpart B—Active Ingredients

338.10 Nighttime sleep-aid active ingredients.

Subpart C—Labeling

338.50 Labeling of nighttime sleep-aid drug products.


SOURCE: 54 FR 6826, Feb. 14, 1989, unless otherwise noted.

Subpart A—General Provisions

§ 338.1 Scope.

(a) An over-the-counter nighttime sleep-aid drug product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this part and each general condition established in §330.1 of this chapter.

(b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.